Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury by Po Wang et al.
RESEARCH Open Access
Class I PI3K inhibitor ZSTK474 mediates a
shift in microglial/macrophage phenotype
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Abstract
Background: Microglia/macrophages play a critical role in the inflammatory and immune processes of cerebral ischemia/
reperfusion injury. Since microglia/macrophages can reversibly shift their phenotype toward either a “detrimental” or a
“restorative” state in the injured central nervous system (CNS), compounds mediate that shift which could inhibit
inflammation and restore the ability to alleviate cerebral ischemia/reperfusion injury would have therapeutic potential.
Methods: Transient middle cerebral artery occlusion was induced in male C57BL/6 mice. Mice were randomly
separated into a sham-operated group, a control group, and a ZSTK474-treated group. We investigated the effect of
ZSTK474 by assessing neurological deficits, infarct volume, and histopathological changes. We then determined the
potential mechanism by immunofluorescent staining, quantitative real-time polymerase chain reaction (PCR), and
Western blot analysis. The Tukey’s test or Mann–Whitney U test was used to compare differences among the groups.
Results: ZSTK474 alleviated neurological deficits and reduced infarct volume in the cerebral ischemia/reperfusion injury
model. Presumably, ZSTK474 shifted the phenotype of microglia/macrophages to a restorative state, since this treatment
decreased the secretion of pro-inflammatory factors and advanced the secretion of anti-inflammatory factors. These
neuroprotective properties of ZSTK474 may be mediated by the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target
of rapamycin complex 1 (mTORC1) pathway.
Conclusions: ZSTK474 can mediate a shift in microglia/macrophage phenotype and inhibit the inflammatory response in
cerebral ischemia reperfusion injury of mice. These effects appeared to ensue via the PI3K/AKT/mTORC1 pathway.
Therefore, ZSTK474 may represent a therapeutic intervention with potential for circumventing the catastrophic aftermath
of ischemic stroke.
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Background
Stroke is a devastating illness, second only to cardiac is-
chemia as a cause of human death worldwide [1]. Eighty-
seven percent of strokes are ischemic [1]. However, no
treatment has been effective thus far in preventing brain
damage in such cases. The only agent now available for
these patients is the enzyme, tissue plasminogen activator
(TPA), but its effectiveness is limited to a short time inter-
val after the ischemic event, when the reperfusion of brain
tissue can be quickly restored [2].
When blood flow is interrupted, the brain becomes is-
chemic which leads to a series of disastrous effects such as
lack of nutrient delivery and accumulation of toxic sub-
stances. The brain is exceedingly vulnerable to neurologic
damage because it does not store oxygen and glycogen
but instead relies on delivery of those substances by the
blood. Re-establishment of blood flow to ischemic areas is
now known as the most effective strategy for treating is-
chemic stroke [3]. But the process of this reperfusion can
increase damage to ischemic brain tissue. Therefore, the
development of a therapy that targets on reperfusion
injury in ischemic stroke is essential, as is a means of
prolonging the treatment time frame beyond the period of
TPA’s effectiveness.
Inflammation plays a key role in the pathogenesis of
stroke. This process partly depends on pro-inflammatory
and anti-inflammatory factors released by immune cells,
such as microglia and macrophages. When reperfusion is
used as a treatment, the ensuing restoration of blood flow
induces a dramatic response from activated microglia/
macrophages as well as severely injurious activity medi-
ated by pro-inflammatory cytokines, such as tumor necro-
sis factor (TNF-α) and interleukins (e.g., IL-6, IL-1β). The
result is exacerbation of tissue damage. One novel strategy
in treating acute cerebral ischemia and reperfusion injury
is to dampen this inflammation indirectly by adjusting
microglial/macrophage phenotype, which in turn “short
circuits” a cascade of inflammatory responses.
In the normal healthy brain, microglia acts as surveil-
lance “sensors.” They endlessly monitor and respond to
changes in the brain’s microenvironment. Microglia and
macrophages, which can reversibly shift their functional
phenotype through a multitude of patterns in response
to changes of the microenvironment [4], have the cap-
acity to elicit a nonspecific innate immune response
when ischemic reperfusion injury occurs [5]. However,
this immune response induces restorative as well as det-
rimental effects. In the detrimental form, they release
pro-inflammatory mediators that can hinder CNS repair,
leading to more serious tissue damage. The restorative
form of microglia/macrophages promotes brain regener-
ation and recovery by clearing cell debris, resolving local
inflammation, and releasing protective factors. These
characteristics of microglia/macrophages mandate their
likely value as a novel target for treating cerebral ische-
mia. Therefore, a major thrust of research on ischemic
stroke is to find methods to suppress the deleterious ef-
fects of microglia/macrophages without compromising
neurovascular repair and remodeling [6].
ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4, 6-
dimorpholino-1, 3, 5-triazine] is one of PI3K inhibitors
that have promising antitumor effects while lacking ob-
servable toxicity. Since this compound has been tested
as an anticancer drug in phase I clinical trials [7–10],
some basic knowledge has been gained about its effects
in humans. Previous research has demonstrated, for ex-
ample, that ZSTK474 has anti-inflammatory properties
which could protect mice from collagen-induced arth-
ritis and multiple sclerosis, both of which are auto-
immune inflammatory diseases [11–13]. Since those
findings indicate that ZSTK474 has anti-inflammatory
and immunoregulatory potential, it is reasonable to
hypothesize that ZSTK474 may improve the prognosis
of patients with cerebral ischemia/reperfusion injury by
inhibiting the inflammatory response. In the present
study, we used mice suffered from middle cerebral artery
occlusion (MCAO) to mimic cerebral ischemia/reperfu-
sion injury in humans.
Methods
Animals
Male C57BL/6 mice (aged 10–12 weeks) were purchased
from Charles River Laboratories (Beijing, China). The mice
were maintained in a temperature-controlled environment
under a 12-h light and 12-h dark cycle. Normal amounts of
food and water were provided. Experiments were per-
formed according to national regulations and were ap-
proved by the Animal Experiments Ethical Committee of
Tianjin Medical University General Hospital. Mice were
allowed to acclimate to the conditions for 1 week.
Induction of MCAO
Cerebral infarction was simulated by occlusion of the
left middle cerebral artery using the methods reported
by Longa et al. [14]. First, mice were anesthetized with
the intraperitoneal (i.p.) injection of chloral hydrate
(30 mg/kg). Second, a midline neck incision was made
to expose the left common carotid artery, the external
carotid artery, and the internal carotid artery; each of
them was then isolated and ligated. A monofilament
with a silicone-beaded tip (xinong, Beijing, China) was
introduced into the internal carotid artery through the
common carotid artery. Mild resistance to the tip’s inser-
tion indicated the blocking of all blood flow from the
posterior cerebral artery, the internal carotid artery, and
the anterior artery. One hour after the occlusion of
blood, the monofilament was removed and blood flow
was restored. Regional cerebral blood flow (rCBF) was
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monitored by Laser Doppler Flowmeter (PF5010) with a
flexible fiber optic probe fixed to the skull above the ter-
ritory of the left middle cerebral artery (rCBF decreased
by 85 %). In the sham-operated group, mice underwent
the same surgical protocol except insertion of the mono-
filament into artery. Body temperature was maintained
within a normal range (37 to 38 °C) by a temperature-
controlled heating pad. Food and water were provided
ad arbitrium. For analgesia, buprenorphine was adminis-
tered i.p. at the dose of 0.03 mg/kg every 12 h for 24 h.
Treatment with ZSTK474
ZSTK474 was provided by the Zenyaku Kogyo Co.
(Tokyo, Japan). ZSTK474 was suspended in 5 % hydro-
xypropylcellulose in water as a solid dispersion. First,
mice were randomly assigned to receive different doses
of ZSTK474 (50, 100, 200, and 300 mg/kg) to determine
the optimum dose; in our experiment, the optimum dose
was 200 mg/kg (Additional file 1: Figure S1). Then mice
were randomly assigned to one of three groups: a sham-
operated group (phosphate-buffered saline, PBS); a con-
trol group (MCAO + PBS); a ZSTK474-treated group
(MCAO + ZSTK474). In the ZSTK474-treated group,
the mice were given the optimum dose of 200 mg/kg
ZSTK474. In the sham-operated group and control
group, mice were given an equivalent volume of PBS. All
mice received that same dose daily via oral gavage begin-
ning at 6 h after the onset of focal ischemia and continu-
ing for two more days, i.e., for a total of 3 days.
Assessment of neurological outcome following MCAO
Ten mice from each group were used for neurobehav-
ioral testing. Mice underwent neurobehavioral testing at
24, 48, and 72 h after MCAO. These tests, including the
modified neurological severity score (mNSS), the corner
test, adhesive removal test, and foot fault test were ad-
ministered as described in the following text. The obser-
ver/scorer was blinded to the experimental conditions.
The mNSS [15] is a composite test of motor, sensory, re-
flex, and balance. Neurological function was graded on a
scale of 0 to 18, with a score of 0 being normal and a
score of 18 denoting maximum deficits. For the severity
scores of injury, one point was recorded for the inability
to perform a test or for the lack of performing a tested
reflex. Therefore, higher scores reflected greater injury.
In the corner test [16], a mouse was placed between
two boards, each 30 × 20 × 1 cm in size. The edges of the
two boards were attached at a 30° angle with a small
opening along the joint placed between the two boards
to encourage the mice to enter the corner. At the begin-
ning of a trial, the mouse was placed between the two
angled boards facing the corner, halfway to the corner.
When the mouse was wedged into the corner, both sides
of its body were stimulated simultaneously. The mouse
usually reared and turned either to the right or left. Each
mouse was tested for 10 trials and the side to which it
turned (right or left) when stimulated was recorded. If a
mouse turned without rearing (i.e., ventral turning), the
trial will not be recorded. Rather, it was repeated at the
end of the session. In general, a non-ischemic mouse
turned either to its left or right, whereas a mouse suf-
fered from MCAO preferentially turned toward its non-
impaired ipsilateral side. The data were expressed as the
percentage of right turns as a function of the total num-
ber of turns and then these were statistically analyzed.
The adhesive removal test [17–19] assessed somatosen-
sory and motor deficits. All mice were trained for this test
before undergoing MCAO. After the mouse familiarized
with the testing environment, two small pieces of adhesive
paper dots were attached to the distal-radial region on the
wrist of each forelimb with equal pressure. The time it took
for the mouse to remove each paper dot (stimulus) from its
forelimbs was recorded for 3 trials per day for each fore-
limb. Individual trials were separated by at least 5 min.
After three consecutive days of training, all the mice were
able to remove the dots. Then they were subjected to
MCAO. The time a mouse took to remove the two dots
from its forelimbs was recorded for statistical analysis.
In the foot fault test [20], a mouse was placed on a hori-
zontal grid floor for 1 min. A foot fault occurred when the
mouse inaccurately placed its forelimb or hindlimb and
fell through one of the grid openings. The number of foot
faults was recorded for statistical analysis.
Infarct volume analysis
When the observation period ended, the mice were anes-
thetized with chloral hydrate (30 mg/kg, i.p.) and perfused
intraventricularly with PBS (pH 7.4, 4 °C). Then, the
brains were quickly acquired for histological assessment of
infarct volume. The brains were sectioned into coronal
sections (2 mm thick) starting from the frontal tips. The
sections were stained with 1 % 2, 3, 5-tripenyltetrazolium
chloride (TTC; Sigma) at 37 °C for 20 min and then fixed
in 4 % paraformaldehyde at 4 °C for 2 h. With TTC, viable
tissues based on intact mitochondrial function were
stained deep red, whereas infarcted tissues remained
unstained. The infarcted areas were evaluated using
Image-Pro® Plus, v. 4.0 image analysis software (Media
Cybernetics). To compensate for the effect of brain
edema, the infarct volume percentage was calculated as
follows: infarct area × {1 − [(ipsilateral hemisphere area −
contralateral hemisphere area)/contralateral hemisphere]}.
The infarct volume was expressed as a percentage of the
volume of the hemisphere contralateral to the infarct [21].
Histopathological analysis
After 72 h of reperfusion, the mice were anesthetized with
chloral hydrate (30 mg/kg, i.p.) and intraventricularly
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perfused with PBS (pH 7.4, 4 °C). The brains were removed
and fixed in 4 % paraformaldehyde overnight at 4 °C. After
paraffin embedding of coronal sections (6 μm), the sections
were stained with hematoxylin and eosin (H&E). Patho-
logical and histological changes were observed through a
light microscope (Olympus) at a magnification of ×20 and
then documented by digital photography.
Immunofluorescent staining and analysis
Animals were first anesthetized and then intraventricularly
perfused with PBS (pH 7.4, 4 °C). The fixed brains were
removed and then immersed in 30 % sucrose in PBS over-
night at 4 °C. Coronal sections (8 μm) were prepared
using a standard cryostat, and the cut sections were stored
at −20 °C until staining. For immunostaining, sections
were blocked in 10 % fetal bovine serum supplemented
with 0.3 % Triton X-100 for 1 h at room temperature. Sec-
tions were next incubated with a combination of primary
antibodies at 4 °C overnight. Primary antibodies included:
goat anti-CD206 (1:200, R&D Systems) (double staining),
rat anti-CD16/32 (1:500, BD) (double staining), rabbit
anti-ionized calcium binding adaptor molecule 1 (Iba-1)
(1:500, Wako) (single or double staining), and rabbit anti-
glial fibrillary acidic protein (GFAP) (1:1000, Abcam)
(single staining). Sections were next washed three times in
PBS before incubated with two secondary antibodies for
1 h at room temperature. Images were taken using a fluor-
escence microscope (Olympus PX51, Olympus Corpor-
ation) and analyzed with Adobe Photoshop 5.0 software.
The cell numbers were determined by counting labeled
cells in three randomly selected microscopic fields across
three slides in the penumbra of the ipsilateral cortex. Data
are expressed as the mean number of cells per visual field
for Iba-1 and GFAP and as the percentage of CD16/32+ or
CD206+ cells to Iba-1+ cells.
Quantitative real-time PCR
Using TRIzol reagent (Invitrogen), total RNA was ex-
tracted from the infarcted hemisphere according to the
manufacturer’s instructions. We quantified the concen-
tration of RNA with ultraviolet spectrophotometry at
260/280 nm. Complementary DNA (cDNA) was tran-
scribed using Trans-Script First-Strand cDNA Synthesis
SuperMix Kit (Transgen) in accordance with the manu-
facturer’s instructions. PCR was performed on an Opti-
con 2 Real-Time PCR Detection System (Bio-Rad) with
SYBR gene PCR Master Mix (Roche). Using the 2–ΔΔCt
method, samples were run in triplicate and normalized
to GAPDH. Then, the expression levels of messenger
RNAs (mRNAs) were reported as fold changes vs. con-
trol. The primer sequences used to measure gene ex-
pression are listed in Table 1.
Quantitative enzyme-linked immunosorbent assay (ELISA)
for cytokine profile
Tissue samples were taken from ischemic region of the
brain. Protein levels of TNF-α, IL-6, IL-1β, IL-10, and
transforming growth factor-β (TGF) were quantified using
an enzyme-linked immunosorbent assay kit (Mosaic
ELISA system, R&D systems) according to the manufac-
turer’s protocol. Determinations were performed in dupli-
cate on individual mouse brains (n = 6 mice per group).
Readings from each sample were normalized for protein
concentration.
Western blot analysis
Ischemic brain tissue was homogenized by sonication in
ristocetin-induced platelet aggregation (RIPA) buffer,
containing protease and phosphatase inhibitors (Roche
Diagnostics). Protein concentration was assessed using a
Protein Assay Kit (Bio-Rad). Proteins were separated on
a 12 % Tris-Glycine gradient gel (Bio-Rad) from 80 to
120 V, then transferred onto nitrocellulose membranes
Table 1 Primers for real-time polymerase chain reaction
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for 1.5 h at 4 °C at 80 V. Membranes were blocked in
5 % BSA for 1 h at room temperature, incubated with
primary antibody overnight at 4 °C, washed three times
for 10 min each at room temperature, incubated with an
HRP-coupled secondary antibody for 1 h, and washed
three times for 10 min each at room temperature. All in-
cubations were performed in TBS buffer including 0.1 %
Tween-20. The following primary antibodies were used:
rabbit anti-pho-p70-S6k (1:1000, Cell Signaling); rabbit
anti-AKT (1:1000, Cell Signaling) and anti-p-AKT (1:
1000, Cell Signaling); mouse anti-GAPDH (1: 1000,
Sigma-Aldrich). Finally, images of Western blots were
captured by densitometry (Bio-Rad).
Statistical analysis
Each experiment was repeated for three times. The
data were expressed as means ± SD. Statistical analysis
was performed using two-way analysis of variance
(ANOVA) followed by the Bonferroni post test. One-
way ANOVAs were followed by Tukey’s test or
Mann–Whitney U tests. SPSS 17.0 (SPSS Inc.) was
used for the statistical analysis. P < 0.05 was consid-
ered statistically significant.
Results
ZSTK474 decreases neurological defects, prevents
histopathological changes, and reduces infarct volume
In mice subjected to MCAO, treatment with ZSTK474
was tested at dosages of 50, 100, 200, and 300 mg/kg.
Since the 200 mg/kg dose produced significant improve-
ment and no obvious toxic effects (P < 0.01) (Additional
file 1: Figure S1), mice were treated with ZSTK474 at a
dose of 200 mg/kg/day daily for three post-MCAO days
during the remaining experiments of this study. Neuro-
logical function was examined in mice suffered from
MCAO followed by 24, 48, and 72 h of reperfusion. In the
ZSTK474 group, neurological function scores were signifi-
cantly better than the control group except the corner
test, as shown in Fig. 1a–d.
Compared with control group (MCAO+ PBS), the
ZSTK474-treated group (MCAO+ZSTK474) had smaller
infarct volumes (P < 0.05) (Fig. 1f). After sectioning of
brain tissues, representative histological sections of the
brain showed that normal regions unaffected by the stroke
were stained red, whereas the infarcted areas were pale in
color (Fig. 1e). No signs of infarction were noted in mice
in the sham-operated group. By using TTC staining, the
infarct areas of brains were clearly visible.
Fig. 1 ZSTK474 alleviates neurological deficits and reduces infarct volume in a model of ischemic reperfusion. a–d Neurological deficits were
evaluated at 24, 48, and 72 h after reperfusion. ZSTK474 markedly alleviate the modified neurological severity scores, adhesive removal test,
and foot fault test compared to mice in the control group. There was no obvious change in corner test outcomes between ZSTK474-treated and
control groups. e Representative TTC-stained brain sections of mice treated with 200 mg/kg ZSTK474 after MCAO (samples acquired at 72 h after
stroke). f Quantitative analysis of the percentage of brain infarct volume. ZSTK474 treatment reduced the percentage of brain infarct volume to a
level of statistically significant difference compared to the control group. g H&E staining showed that neurons had normal morphologic features
in the sham-operated group. The MCAO group presented with multiple vacuolated interspaces, infiltration of inflammatory cells, and dead
neurons. ZSTK474 significantly ameliorated the damage caused by reperfusion injury. h Quantitative analysis of the number of inflammatory cells
in G. Data expressed as means ± SD; #P < 0.01, *P < 0.05, vs. control group; n = 6–10 per group
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Subsequently, brain tissues were stained with H&E to
detect neuronal loss and vacuolated interspaces. Brain
tissues were acquired from mice subjected to 1 h of is-
chemia followed by 72 h of reperfusion. In brain slices
from the control group, no intact neurons were present
in ischemic areas (Fig. 1g). By contrast, the same areas
in brain slices of the ZSTK474-treated group showed
only partial neuronal loss, and a few neurons remained
intact in the vacuolated spaces (Fig. 1g). Quantitative
analysis indicated that the total number of infiltrating
cells had significantly decreased in the ZSTK474-treated
group compared to controls in the ischemic penumbra
(P < 0.05) (Fig. 1h).
ZSTK474 inhibits the expression of Iba-1 and GFAP in the
ischemic penumbra
Since ischemia/reperfusion can stimulate microglia/mac-
rophages and astrocytes [22, 23], we investigated such
changes by using immunofluorescence to detect their re-
spective markers, Iba-1 and GFAP. As shown in Fig. 2, the
microglia/macrophage in the sham group was highly
ramified, with their cells exhibiting long increased and
branches of Iba-1-stained microglia/macrophages became
short, retracted, and thick. Compared with the control
group, the ZSTK474-treated group had decreased micro-
glial/macrophage numbers and showed smaller cellular
bodies (P < 0.001) (Fig. 2a, c). A similar pattern of results
was obtained with immunostaining for GFAP, which spe-
cifically identifies astrocytes (P < 0.05) (Fig. 2b, d).
In Western blots, the protein level of Iba-1 increased
significantly 72 h after ischemia reperfusion. In contrast,
this trend was obviously suppressed in the ZSTK474-
treated group (P < 0.05) (Fig. 2e, f ). These data indicate
that ZSTK474 inhibited the expression of Iba-1 in the
ischemic penumbra.
ZSTK474 shifts the phenotype of microglia/macrophages
to a restorative state
Microglial/macrophage phenotypes can be distinguished
by their expression of characteristic surface marker genes.
In double immunofluorescence staining, the expression of
CD16/32, a marker of the detrimental state, was strongly
present in Iba1+ cells (microglia/macrophages) in MCAO
mice. That expression was significantly reduced in the
ZSTK474-treated group (P < 0.05) (Fig. 3a, c). In contrast,
co-expression of the restorative state markers, CD206 and
Iba1, was higher in the ZSTK474-treated group compared
with the control group (P < 0.05) (Fig. 3b, d). These results
Fig. 2 ZSTK474 inhibits the expression of Iba-1 and GFAP at 72 h after cerebral reperfusion injury. GFAP and Iba-1 are specific markers of microglia/
macrophages and astrocytes. a, b The number of microglia/ macrophages and astrocytes increased as demonstrated by immunofluorescent staining.
However, ZSTK474 administration decreased the number of Iba-1-stained and GFAP-stained cells. c, d Quantification of microglial/macrophage and
astrocyte numbers of A, B. e, f Protein levels of Iba-1 were dramatically lower in the ZSTK474-treated group, as demonstrated by Western blotting.
Magnification: ×20 in A and B. Data in graphs are expressed as means ± SD; #P < 0.001, *P < 0.05, vs. control group; n = 3
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suggest not only that microglia/macrophages largely trans-
form to a detrimental status in the absence of ZSTK474
but also shift from detrimental state to a restorative state
after MCAO in the presence of ZSTK474.
Quantitative real-time PCR produced results consistent
with those of double immunofluorescence staining. Com-
pared with the control group, the ZSTK474-treated group
expressed a far lower value for the detrimental state’s
mRNA markers (CD16, CD32, and CD86), whereas the
mRNA markers of restorative state (CD206, YM-1, and Arg
1) were induced dramatically at 72 h (Fig. 3e, f). These data
show that ZSTK474 can convert the phenotype of micro-
glia/macrophages to the restorative state, which produces a
neuroprotective effect.
ZSTK474 inhibits pro-inflammation and promotes anti-
inflammatory processes
Secretion of inflammatory cytokines is a key event that
follows ischemic stroke. We detected the expression of
mRNAs for various inflammatory cytokines (IL-1β, TNF-α,
IL-6, IL-10, and TGF-β) in the cortex ipsilateral to sites of
ischemia 24, 48, and 72 h after reperfusion (Fig. 4a–e).
Generally, expression of these cytokines increased soon
after reperfusion. TNF-α and IL-6 expression peaked at
24 h. IL-1β and TGF-β expression peaked at 48 h. IL-10
was rising continuously. However, in the presence of
ZSTK474, increases in expression of TNF-α, IL-6, and IL-
1β were blunted (Fig. 4a–c). IL-1β expression was most
significantly affected by ZSTK474 at 48 h after ischemia
reperfusion injury. TNF-α, IL-6, and IL-1β are pro-
inflammatory factors that can aggravate the reperfusion
injury. TGF-β and IL-10 are anti-inflammatory factors that
are regarded as beneficial cytokines, since they reduce
inflammation and immune reactions [24]. In our control
group, IL-10 expression increased by 2.6-fold at 48 h com-
pared to the sham-operated group (Fig. 4d). ZSTK474
treatment increased IL-10 expression by 4.5-fold compared
to that of the control group (Fig. 4d). We also observed
higher levels of TGF-β expression in the ZSTK474-treated
group at 48 h compared to the control group (Fig. 4e).
According to the results of PCR, we found that control
group and ZSTK474-treated group have significant differ-
ence at 48 h after MCAO. So, we used ELISA kits to ana-
lysis the protein levels of cytokine in the ischemic brain
Fig. 3 Double immunofluorescent staining for the microglial/macrophage marker Iba-1 and detrimental or restorative state markers. Brain sections
were prepared 72 h after MCAO. a Double immunofluorescent staining for CD16/32 (red; detrimental state marker) and Iba-1 (green). b Double
immunofluorescent staining for CD206 (red; restorative state marker) and Iba-1 (green). c Quantification of the percentage of CD16/32+/Iba-1+ cells.
d Quantification of the percentage of CD206+/Iba-1+ cell. e, f PCR was performed to quantify the mRNA expression of detrimental state markers
(CD16, CD32, CD86) and restorative state markers (CD206, YM-1, Arg1) in the ipsilateral cortex 72 h after MCAO. Data in graphs are expressed as
means ± SD; #P < 0.001, *P < 0.05 vs. control group; n = 3–6
Wang et al. Journal of Neuroinflammation  (2016) 13:192 Page 7 of 11
tissues at 48 h of reperfusion. As shown in Fig. 4f, the pro-
duction of pro-inflammatory cytokines (IL-1β and TNF-α)
in the ZSTK474-treated group was significantly reduced
compared to the control group. However, there were no
marked differences in the levels of IL-6 in the two groups
(Fig. 4f). The production of anti-inflammatory cytokines
(IL-10 and TGF-β) in the ZSTK474-treated group notably
exceeded that in the control group (Fig. 4f).
ZSTK474-related neuroprotection is mediated by the
PI3K/AKT/mTORC1 pathway
ZSTK474 inhibits the phosphorylation of AKT, a major tar-
get of PI3K, thereby downregulating downstream signaling
components. In our study, ZSTK474 treatment decreased
the level of phosphorylated AKT (Ser-473) but did not alter
total AKT protein levels (Fig. 5a–c). We next assessed
whether ZSTK474 treatment affects the levels of mTORC1,
a downstream component of the PI3K/AKT/mTORC1
pathway. The mechanism of this effect was ZSTK474’s in-
hibition of phosphorylation of the p70 ribosomal protein,
S6 kinase (p70S6k), on Thr-389 (P < 0.05) (Fig. 5a, d, e),
confirming that ZSTK474 reduced the level of AKT and
p70S6k phosphorylation in this MCAO model.
Discussion
Microglia/macrophages play a critical role in the inflam-
matory and immune processes of cerebral ischemia/reper-
fusion injury; thus, a compound that moderates the
activities of microglia and macrophages may have thera-
peutic potential for preventing otherwise crippling injury
[25]. In the present study, we found evidence for the utility
of this treatment option by assessing the effect of the PI3K
inhibitor, ZSTK474. In mice that experienced ischemic/re-
perfusion injury, we found that treatment with ZSTK474
inhibited the expression of Iba-1 and GFAP in the ische-
mic penumbra, altered the phenotype of microglia/macro-
phages to a restorative state, reduced the production of
pro-inflammatory cytokines, increased the production of
anti-inflammatory cytokines, and ultimately improved
neurological outcome. This original study suggests that
ZSTK474 may have neuroprotective power that mitigates
cerebral ischemic/reperfusion injury by fostering a benefi-
cial microglial/macrophage phenotype.
Our research indicated that the IPI3K inhibitor,
ZSTK474, could mediate the function of microglia/macro-
phages after ischemia/reperfusion injury. Here, as expected,
ZSTK474 treatment diminished the secretion of pro-
Fig. 4 ZSTK474 inhibits pro-inflammatory cytokines and promotes anti-inflammatory cytokines. PCR was performed to quantify the expression
of IL-1β (a), IL-6 (b), TNF-α (c), IL-10 (d), and TGF-β (e) mRNAs in the ischemic region 24, 48, and 72 h of reperfusion. In protein level, the
supernatants of brain tissues from mice that underwent 48 h of reperfusion were measured by ELISA kits (f). Data in graphs are expressed as
means ± SD; #P < 0.001, *P < 0.05 vs. control group; n = 6
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inflammatory cytokines and enhanced the secretion of anti-
inflammatory cytokines at multiple time points. Pro-
inflammatory mediators (such as IL-6, IL-1β, and TNF-α)
contribute to expanding the area of brain injury in the
context of stroke [26, 27]. Indeed, other studies showed that
intraventricular injection of TNF-α and IL-1 increased
infarct volume and brain edema after MCAO in rats,
whereas injection of the microglia inhibitor, minocycline,
suppressed microglial activation and the expression of pro-
inflammatory cytokines [28]. To the contrary, IL-10 and
Fig. 5 ZSTK474 reduces P-AKT and P-p70S6k protein levels. ZSTK474 suppresses phosphorylation of AKT and other downstream compounds.
Western blots (a) and densitometry histograms (b–e) showing AKT, P-AKT, p70S6k, and P-p70S6k protein levels in ZSTK474-treated, control, and
sham-treated mice following MCAO. P-AKT and P-p70S6k protein levels were dramatically decreased in the ZSTK474-treated group. Total AKT and
p70S6k protein level, however, remained unchanged. Data in graphs are expressed as means ± SD; #P < 0.001, *P < 0.05 vs. control group; NS, not
significant; n = 6
Fig. 6 Summary diagram illustrates a hypothesis for how ZSTK474 exerts its effects on ischemic reperfusion injury. Administration of ZSTK474
after cerebral ischemic reperfusion injury decreases the number of microglia/macrophages and shifts their phenotype toward the more
restorative state. This treatment reduces the level of pro-inflammatory cytokines and enhances the level of anti-inflammatory cytokines secreted.
ZSTK474, a member of a specific class of IPI3K inhibitors, inhibits the phosphorylation of AKT to downregulate downstream mediators.
The beneficial effects of ZSTK474 that we observed may result from inhibition of the mTORC1 pathway, which is an important downstream
mediator of AKT-adjusted cell growth and translation
Wang et al. Journal of Neuroinflammation  (2016) 13:192 Page 9 of 11
TGF-β are pleiotropic immunoregulatory cytokines that
play a key role in the inflammatory response associated
with tissue recovery [24, 29]. Production of the latter cyto-
kines is promoted by phagocytosis and occurs in concert
with the removal of dead cells [30]. Here, we found that
ZSTK474 treatment not only reduced pro-inflammation
production but also increased the levels of TGF-β and IL-10
mRNAs within 24–72 h after ischemic/reperfusion injury.
AKT is known to control cell growth through the phos-
phorylation of downstream mTOR complex 1 (mTORC1)
which mediates the direct phosphorylation of p70S6k and
the leukocyte initiation factor 4E-binding protein [31].
The PI3K/AKT/mTORC1 pathway plays an important
role in translation initiation, transcription, cytoskeleton
organization, cell growth, proliferation, and cell survival.
In accord, our results showed that ZSTK474 inhibited the
phosphorylation of AKT and simultaneously reduced
phosphorylation levels of p70S6k. This indicates that
ZSTK474 may modulate the function of microglia/macro-
phages through the PI3K/AKT/mTORC1 pathway (Fig. 6).
Although some studies performed in vivo and in vitro
have shown that the PI3K/AKT/mTORC1 pathway closely
relates to microglia/macrophages, the conclusion is con-
troversial [32–34]. The inhibition of mTORC1 is also be-
lieved to prevent the microglial/macrophage phenotype
toward to a detrimental state, significantly enhancing
beneficial anti-inflammatory activity and decreasing the
production of pro-inflammatory cytokines and chemo-
kines [33]. Others have suggested that PI3K/AKT, GSK-3,
and mTORC1 pathways are potential targets for the devel-
opment of novel strategies to modulate neuroinflamma-
tion [34]. Another point of view is that the upregulation of
PI3K/AKT and its downstream pathway could inhibit the
activation of microglia in vitro [35, 36]. TP and DAHP are
also thought to decrease cell apoptosis in the focal cere-
bral ischemia of rat brains by a mechanism related to acti-
vation of the PI3K/AKT/mTORC1 pathway [37]. Since
the cell signal transduction pathway of PI3K/AKT/
mTORC1 is a complex and dynamic biological process in-
volving negative feedback, the controversial nature of
these conjectures is understandable.
Therefore, we sought a balance in the inflammatory re-
sponse, the effect of which would resolve these issues.
ZSTK474 is a weaker inhibitor of mTORC1 than the PI3K
isoforms [9] and its induction of apoptosis is also weaker
and cell type-dependent [7]; therefore, we intuited its effect
may be more modest. In that framework, the study we de-
signed for using ZSTK474 focused only on the inflamma-
tory response. Certainly, further research will illustrate the
important role of PI3K/AKT/mTORC1 and its downstream
pathway in microglial/macrophage phenotype.
The present study has some limitations that should
be considered. Firstly, PI3Kδ and PI3Kγ are key en-
zymes in leukocyte signaling and are promising agents
for interventions that target signaling pathways involved in
inflammatory and autoimmune diseases [38, 39]. ZSTK474
as a pan PI3K inhibitor possesses anti-inflammatory poten-
tial that may be related to PI3Kδ and PI3Kγ. But our re-
search focused only on the PI3K/AKT/mTORC1 pathway.
Secondly, this study did not fully assess the effects of
ZSTK474 on astrocytes, despite evidence indicating that in-
hibition of astrocyte activation enhances neuronal survival
and improves outcomes after cerebral ischemia and related
reperfusion injury.
Conclusions
In conclusion, our results demonstrated that ZSTK474 in-
duced a shift in microglial/macrophage phenotype, inhib-
ited inflammatory responses, reduced infarct volume, and
improved neurological function in an experimental model
of cerebral ischemia/reperfusion injury. These effects ap-
peared be mediated by the PI3K/AKT/mTORC1 pathway.
Our findings established a sound foundation for develop-
ing a therapeutic strategy that may benefit the patients
who endure ischemic stroke.
Additional file
Additional file 1: Figure S1. ZSTK474 alleviates neurological deficits in
the model of ischemic reperfusion. (DOCX 56 kb)
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